The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 21, 2015

Filed:

May. 16, 2012
Applicants:

Jonathan Liu, Milpitas, CA (US);

Mark Thompson, Morgan Hill, CA (US);

Luis J. Maranga, Santa Clara, CA (US);

Floro Cataniag, Pittsburg, CA (US);

Simon S. Hsu, Palo Alto, CA (US);

Inventors:

Jonathan Liu, Milpitas, CA (US);

Mark Thompson, Morgan Hill, CA (US);

Luis J. Maranga, Santa Clara, CA (US);

Floro Cataniag, Pittsburg, CA (US);

Simon S. Hsu, Palo Alto, CA (US);

Assignee:

MEDIMMUNE, LLC, Gaithersburg, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 7/02 (2006.01); A61K 39/145 (2006.01);
U.S. Cl.
CPC ...
C12N 7/02 (2013.01); A61K 39/145 (2013.01); C12N 2760/16051 (2013.01); C12N 2760/16134 (2013.01); C12N 2760/16151 (2013.01); C12N 2760/16234 (2013.01); C12N 2760/16251 (2013.01);
Abstract

The present invention provides novel serum-free cell culture medium and methods for cultivating MDCK cells. In particular, non-tumorigenic MDCK cells. The present invention also provides methods for producing influenza viruses (e.g., particularly cold-adapted, and/or temperature sensitive, and/or attenuated influenza viruses) that eliminate the need for a cell culture medium exchange step. The novel medium and methods are useful to grow influenza viruses, in cell culture to high titer. The present invention further provides purification methods for purifying influenza viruses with high overall recovery of live virus and result in levels of host cell DNA (HCD), host cell protein (HCP) and non-specific endonuclease (e.g., Benzonase), which are below the specifications required by regulatory agencies. The immunogenic compositions can be used to actively immunize subjects or to generate antibodies for a variety of uses, including passive immunization and diagnostic immunoassays.


Find Patent Forward Citations

Loading…